Does IDELALISIB Cause Second primary malignancy? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Second primary malignancy have been filed in association with IDELALISIB (Zydelig). This represents 0.2% of all adverse event reports for IDELALISIB.
10
Reports of Second primary malignancy with IDELALISIB
0.2%
of all IDELALISIB reports
2
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From IDELALISIB?
Of the 10 reports, 2 (20.0%) resulted in death, 2 (20.0%) required hospitalization, and 1 (10.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IDELALISIB. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does IDELALISIB Cause?
Disease progression (1,204)
Death (779)
Diarrhoea (752)
Off label use (548)
Pneumonia (426)
Pyrexia (371)
Drug ineffective (294)
Fatigue (284)
Dehydration (242)
Dyspnoea (206)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which IDELALISIB Alternatives Have Lower Second primary malignancy Risk?
IDELALISIB vs IDURSULFASE
IDELALISIB vs IFOSFAMIDE
IDELALISIB vs IGURATIMOD
IDELALISIB vs ILOPERIDONE
IDELALISIB vs ILOPROST